Vertex Pharmaceuticals Inc 2025 SR
The report highlights Vertex's progress in 2025, including the launch of JOURNAVX in acute pain and ALYFTREK in cystic fibrosis. The company achieved a 49% reduction in absolute Scope 1 and 2 greenhouse gas emissions since 2014 and operated over 1.6 million square feet of green-certified facilities. Vertex and the Vertex Foundation contributed approximately $51 million in community giving, and 83% of employees participated in the annual Global Week of Service. Additionally, the company maintained a strong safety record with a Total Recordable Incident Rate of 0.13.
Company: Vertex Pharmaceuticals Inc
Sector: Health Care
Country: United States
Year: 2025
Type: SR
Pages: 43
Vertex Pharmaceuticals Inc
Corporate Responsibility Report
The report highlights Vertex's progress in 2025, including the launch of JOURNAVX in acute pain and ALYFTREK in cystic fibrosis. The company achieved a 49% reduction in absolute Scope 1 and 2 greenhouse gas emissions since 2014 and operated over 1.6 million square feet of green-certified facilities. Vertex and the Vertex Foundation contributed approximately $51 million in community giving, and 83% of employees participated in the annual Global Week of Service. Additionally, the company maintained a strong safety record with a Total Recordable Incident Rate of 0.13.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
2025
Fiscal Year
2025
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Renewable Energy
Water Consumption
Total Waste
Employees